Recurrent or metastatic squamous cell carcinoma of head and neck

Clinical trials for Recurrent or metastatic squamous cell carcinoma of head and neck explained in plain language.

Never miss a new study

Get alerted when new Recurrent or metastatic squamous cell carcinoma of head and neck trials appear

Sign up with your email to follow new studies for Recurrent or metastatic squamous cell carcinoma of head and neck, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

An Open-Label, single arm, Multi-Center phase II clinical study to evaluate the efficacy and safety of MRG003 in patients with recurrent or metastatic squamous cell carcinoma of head and neck.

Completed

The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 and the combination of MRG003 and HX008 in patients with recurrent or metastatic squamous cell carcinoma of head and neck.

Matched conditions: RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK

Phase 2 • Sponsor: Lepu Biopharma Co., Ltd.

Last updated Sep 10, 2026 16:00 UTC

Recurrent or metastatic squamous cell carcinoma of head and neck

Get alerted when new Recurrent or metastatic squamous cell carcinoma of head and neck trials appear

An Open-Label, single arm, Multi-Center phase II clinical study to evaluate the efficacy and safety of MRG003 in patients with recurrent or metastatic squamous cell carcinoma of head and neck.